Swiss National Bank Vir Biotechnology, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Swiss National Bank holds 185,200 shares of VIR stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,200

Previous 185,200 -0.0%

Holding current value

$1.29 Million

Previous $1.65 Million 15.84%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$7.76 - $10.29 $48,888 - $64,826	-6,300 Reduced 3.29%	185,200 $1.86 Million
Q3 2023 Nov 08, 2023	BUY	$9.14 - $24.62 $18,280 - $49,240	2,000 Added 1.06%	191,500 $1.79 Million
Q2 2023 Aug 09, 2023	BUY	$23.2 - $27.29 $728,480 - $856,906	31,400 Added 19.86%	189,500 $4.65 Million
Q1 2023 May 10, 2023	SELL	$22.26 - $30.85 $402,906 - $558,385	-18,100 Reduced 10.27%	158,100 $3.68 Million
Q4 2022 Feb 08, 2023	BUY	$19.96 - $28.22 $71,856 - $101,592	3,600 Added 2.09%	176,200 $4.46 Million
Q3 2022 Nov 09, 2022	BUY	$18.26 - $31.1 $49,302 - $83,970	2,700 Added 1.59%	172,600 $3.33 Million
Q2 2022 Aug 09, 2022	BUY	$19.08 - $26.7 $290,016 - $405,840	15,200 Added 9.83%	169,900 $4.33 Million
Q1 2022 May 09, 2022	BUY	$21.19 - $40.01 $233,090 - $440,110	11,000 Added 7.65%	154,700 $3.98 Million
Q3 2021 Nov 08, 2021	BUY	$34.9 - $54.54 $97,720 - $152,712	2,800 Added 1.99%	143,700 $6.25 Million
Q2 2021 Aug 06, 2021	BUY	$38.75 - $51.0 $5.46 Million - $7.19 Million	140,900 New	140,900 $6.66 Million

Others Institutions Holding VIR

# of Institutions

219

Shares Held

87.4M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Vir Biotechnology, Inc. Transaction History